Adderall and Adderall IR shortage due to intermittent manufacturing delays at Teva Pharmaceuticals
THURSDAY, Oct. 13, 2022 (HealthDay News) — People with attention-deficit/hyperactivity disorder (ADHD) or narcolepsy may rely on the drug Adderall, but it is in short supply, the U.S. Food and Drug Administration announced Wednesday.
The Adderall and Adderall IR shortage is due to intermittent manufacturing delays at Teva, one of the companies that produces the medication. While other companies continue to produce these amphetamine mixed salts, they do not make enough to meet U.S. demand.
Adderall is FDA-approved for ADHD and narcolepsy. Until supply is restored, alternatives include the extended-release version of amphetamine mixed salts, the FDA said.
The FDA has posted information online on current manufacturers and available product strengths. It is monitoring the shortage and helping manufacturers get what they need to resolve it. The agency said it would continue to provide updates.
Patients should work with their doctors to determine their best treatment option, according to a news release from the FDA Center for Drug Evaluation and Research.
Low Levels of Placental Growth Factor in Pregnancy Linked to Subsequent ADHD in Offspring 
People With ADHD Experience 50 Percent More GI Symptoms 
Problematic Social Media Use Linked to Worsening of ADHD Symptoms 
ADHD Poses Additional Concussion Challenges for Athletes .jpg)
Time-Restricted Eating Shows Possible Benefits for Patients With Huntington Disease 
Past Blast Exposure Tied to Long-Term Chronic Medical Diagnoses in Veterans 
Mortality in Injured Children Linked to Higher SBP Thresholds Than Those That Define Hypotension 
Extreme Heat Linked to 33 Clinically Reportable Diagnoses 
.jpg)
